ClinicalTrials.Veeva

Menu

Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance

U

University Hospital, Strasbourg, France

Status

Unknown

Conditions

Severe Sepsis and Septic Shock

Study type

Observational

Funder types

Other

Identifiers

NCT02391792
DC2012-1633

Details and patient eligibility

About

Microparticules (MPs) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. MPs are know recognized as a pool of bioactive messengers with merging role in pathophysiology of immune and cardiovascular diseases. MPs have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. This a prospective observational study of circulating MPs and blood coagulation in septic shock patients admitted in medical intensive care units (ICUs) of four tertiary hospitals at baseline (D1, D2, D3, D4, D7).

Enrollment

300 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Septic shock (patients)
  • Without septic shock (control)
  • Informed consent

Exclusion criteria

  • Class IV heart failure
  • Child-plugh grade C cirrhosis
  • Cancer under active treatment
  • BMI>35kg/m2
  • Moribund patient
  • DNR decision

Trial design

300 participants in 3 patient groups

patients
Description:
patients with septic shock
control
Description:
patients without septic shock
healthy volunteers

Trial contacts and locations

1

Loading...

Central trial contact

Ferhat MEZIANI, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems